Literature DB >> 25619634

Improving adherence to and persistence with oral therapy of osteoporosis.

M L Bianchi1, P Duca, S Vai, G Guglielmi, R Viti, C Battista, A Scillitani, S Muscarella, G Luisetto, V Camozzi, R Nuti, C Caffarelli, S Gonnelli, C Albanese, V De Tullio, G Isaia, P D'Amelio, F Broggi, M Croci.   

Abstract

UNLABELLED: Osteoporosis treatment has low adherence and persistence. This study evaluated if greater patient involvement could improve them. At 12 months, only 114 out of 344 participants were "fully adherent and persistent" (all drug doses taken throughout the study). Only frequency of drug administration had a significant influence on adherence.
INTRODUCTION: Osteoporosis affects millions of individuals worldwide. There are now several effective drugs, but adherence to and persistence with treatment are low. This 12-month multicenter, prospective, randomized study evaluated the efficacy of two different methods aimed at improving adherence and persistence through greater patient involvement, compared with standard clinical practice.
METHODS: Three hundred thirty-four post-menopausal women, receiving an oral prescription for osteoporosis for the first time, were recruited and randomized into three groups: group 1 (controls, managed according to standard clinical practice) and groups 2 and 3 (managed with greater patient and caregiver involvement and special reinforcements: group 2, instructed to use several different "reminders"; group 3, same "reminders" as group 2, plus regular phone calls from and meetings at the referring Center). All enrolled women had two visits (baseline and 12 months).
RESULTS: Of 334 enrolled women, 247 (74%) started the prescribed therapy. Of those who started, 219 (88.7%) persisted in therapy for at least 10 months. At final evaluation, only 114 women were considered as "fully adherent and persistent" (all doses taken throughout the 12 months). There were no significant differences regarding "full adherence" among the three randomized groups. The frequency of drug administration had a significant influence: weekly administration had a >5-fold higher adherence and monthly administration an 8-fold higher adherence (p < 0.0001) than daily administration.
CONCLUSIONS: The special effort of devising and providing additional reminders did not prove effective. Additional interventions during the follow-up, including costly interventions such as phone calls and educational meetings, did not provide significant advantages.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25619634     DOI: 10.1007/s00198-015-3038-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

Review 1.  The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.

Authors:  Mickaël Hiligsmann; Annelies Boonen; Véronique Rabenda; Jean-Yves Reginster
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-04       Impact factor: 2.217

Review 2.  Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies.

Authors:  Stuart L Silverman; Deborah T Gold; Joyce A Cramer
Journal:  South Med J       Date:  2007-12       Impact factor: 0.954

3.  Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial.

Authors:  Dorthe Nielsen; Jesper Ryg; Winnie Nielsen; Berit Knold; Nis Nissen; Kim Brixen
Journal:  Patient Educ Couns       Date:  2010-04-18

4.  Primary non-adherence to bisphosphonates in an integrated healthcare setting.

Authors:  K Reynolds; P Muntner; T C Cheetham; T N Harrison; D E Morisky; S Silverman; D T Gold; S S Vansomphone; R Wei; C D O'Malley
Journal:  Osteoporos Int       Date:  2013-04-18       Impact factor: 4.507

Review 5.  Adherence with medications used to treat osteoporosis: behavioral insights.

Authors:  John T Schousboe
Journal:  Curr Osteoporos Rep       Date:  2013-03       Impact factor: 5.096

Review 6.  Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.

Authors:  M M Wilkes; R J Navickis; W W Chan; E M Lewiecki
Journal:  Osteoporos Int       Date:  2009-07-02       Impact factor: 4.507

7.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

8.  Osteoporosis medication adherence: physician perceptions vs. patients' utilization.

Authors:  Jeffrey R Curtis; Qian Cai; Sally W Wade; Bradley S Stolshek; John L Adams; Akhila Balasubramanian; Hema N Viswanathan; Joel D Kallich
Journal:  Bone       Date:  2013-03-15       Impact factor: 4.398

Review 9.  Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Authors:  E Hernlund; A Svedbom; M Ivergård; J Compston; C Cooper; J Stenmark; E V McCloskey; B Jönsson; J A Kanis
Journal:  Arch Osteoporos       Date:  2013-10-11       Impact factor: 2.617

10.  Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.

Authors:  Tao Fan; Qiaoyi Zhang; Shuvayu S Sen
Journal:  Clinicoecon Outcomes Res       Date:  2013-11-19
View more
  12 in total

1.  Improving persistence and adherence to osteoporosis treatment: a challenge to solve.

Authors:  T Alarcón; J I González-Montalvo; A Martín-Vega; P Gotor
Journal:  Osteoporos Int       Date:  2015-09-21       Impact factor: 4.507

Review 2.  A systematic review of factors affecting medication adherence among patients with osteoporosis.

Authors:  C T Yeam; S Chia; H C C Tan; Y H Kwan; W Fong; J J B Seng
Journal:  Osteoporos Int       Date:  2018-11-12       Impact factor: 4.507

3.  Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.

Authors:  A Shah; D Prieto-Alhambra; S Hawley; A Delmestri; J Lippett; C Cooper; A Judge; M K Javaid
Journal:  Osteoporos Int       Date:  2016-11-03       Impact factor: 4.507

Review 4.  Improving drug adherence in osteoporosis: an update on more recent studies.

Authors:  Ayesha Jaleel; Kenneth G Saag; Maria I Danila
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-07-10       Impact factor: 5.346

Review 5.  Bone-seeking agents for the treatment of bone disorders.

Authors:  Jacqueline Cawthray; Ellen Wasan; Kishor Wasan
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 6.  Supporting patients to get the best from their osteoporosis treatment: a rapid realist review of what works, for whom, and in what circumstance.

Authors:  Z Paskins; O Babatunde; A Sturrock; L S Toh; R Horne; I Maidment
Journal:  Osteoporos Int       Date:  2022-06-11       Impact factor: 5.071

Review 7.  T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone.

Authors:  Roberto Pacifici
Journal:  Ann N Y Acad Sci       Date:  2015-12-10       Impact factor: 5.691

8.  Parathyroid hormone 1-34 and skeletal anabolic action: The use of parathyroid hormone in bone formation.

Authors:  L Osagie-Clouard; A Sanghani; M Coathup; T Briggs; M Bostrom; G Blunn
Journal:  Bone Joint Res       Date:  2017-01       Impact factor: 5.853

9.  Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China.

Authors:  Ruxu You; Yu Zhang; David Bin-Chia Wu; Jinyu Liu; Xinyu Qian; Nan Luo; Takahiro Mori
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

10.  Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis.

Authors:  S Calabria; E Cinconze; M Rossini; E Rossi; A P Maggioni; A Pedrini; M De Rosa
Journal:  Patient Prefer Adherence       Date:  2016-04-19       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.